CHAOQUN WANG¹, TING ZHANG², CHAOHE ZHANG^3,*

Oncology Research, Vol.32, No.12, pp. 1867-1879, 2024, DOI:10.32604/or.2024.044547 - 13 November 2024

Abstract Background: Drug resistance is the main factor contributing to cancer recurrence and poor prognosis. Exploration of drug resistance-related mechanisms and effective therapeutic targets are the aim of molecular targeted therapy. In our study, the role of long non-coding RNA (lncRNA) AFAP1-AS1 in gemcitabine resistance and related mechanisms were explored in cervical cancer cells. Methods: Gemcitabine-resistant cervical cancer cell lines HT-3-Gem and SW756-Gem were constructed using the gemcitabine concentration gradient method. The overall survival rates and recurrence-free survival rates were evaluated by Kaplan-Meier analysis. The interaction was verified through a Dual-luciferase reporter gene assay and a… More > Graphic Abstract

RUIFANG LI¹, XINRONG NAN^2,*, MING LI^3,*, OMAR RAHHAL³

Oncology Research, Vol.32, No.8, pp. 1323-1334, 2024, DOI:10.32604/or.2024.046965 - 17 July 2024

Abstract Background: Fibroblast activation protein (FAP), a cell surface serine protease, plays roles in tumor invasion and immune regulation. However, there is currently no pan-cancer analysis of FAP. Objective: We aimed to assess the pan-cancer expression profile of FAP, its molecular function, and its potential role in head and neck squamous cell carcinoma (HNSC). Methods: We analyzed gene expression, survival status, immune infiltration, and molecular functional pathways of FAP in The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) tumors. Furthermore, to elucidate the role of FAP in HNSC, we performed proliferation, migration, and invasion assays… More >

SAIFEI XIE^1,2,4, HUI XIE^2,*, JINCAI GUO³, JIN TAN⁴, YULIN YU¹, MINYI ZHANG¹, SHANG WEN¹

BIOCELL, Vol.48, No.4, pp. 591-599, 2024, DOI:10.32604/biocell.2024.046691 - 09 April 2024

Abstract Background: Puerarin (Pue) has been reported to be a natural active ingredient with multiple antifibrotic properties. This work aimed at exploring the function of Pue in oral submucous fibrosis (OSF) treatment. Methods: Human oral mucosa fibroblasts (hOMF) were induced with transforming growth factor beta1 (TGF-β1) and intervened with Pue. Expressions of fibrosis-related markers were analyzed by Western blot and IF staining. Cell viability was characterized by the CCK-8 assay. Expressions of miR-30 family members were quantified by qRT-PCR. The correlation between fibroblast activation protein (FAP) and miR-30 family expression was evaluated by the Pearson correlation… More > Graphic Abstract

SHUIZHONG CEN^1,#, XIAOJIE PENG^2,#, JIANWEN DENG^3,#, HAIYUN JIN⁴, ZHINAN DENG⁵, XIAOHUA LIN³, DI ZHU³, MING JIN⁶, YANWEN ZHU³, PUSHENG ZHANG³, YUNFENG LUO³, HONGYAN HUANG^3,*

Oncology Research, Vol.31, No.3, pp. 375-388, 2023, DOI:10.32604/or.2023.028256 - 22 May 2023

Abstract Triple-negative breast cancer (TNBC) is characterized by fast growth, high metastasis, high invasion, and a lack of therapeutic targets. Mitosis and metastasis of TNBC cells are two important biological behaviors in TNBC malignant progression. It is well known that the long noncoding RNA AFAP1-AS1 plays a crucial role in various tumors, but whether AFAP1-AS1 is involved in the mitosis of TNBC cells remains unknown. In this study, we investigated the functional mechanism of AFAP1-AS1 in targeting Polo-like Kinase 1 (PLK1) activation and participating in mitosis of TNBC cells. We detected the expression of AFAP1-AS1 in the TNBC… More > Graphic Abstract

YANG ZHANG, LIXIA MA, TINGTING ZHANG, PEIDONG LI, JIABIN XU, ZHUO WANG^*

Oncology Research, Vol.29, No.2, pp. 129-139, 2021, DOI:10.32604/or.2022.03563 - 13 July 2022

Abstract In this study, we mainly focus on probing expression profile and detailed functions of long non-coding RNA TFAP2A antisense RNA 1 (TFAP2A-AS1) in non-small cell lung cancer (NSCLC). Moreover, the mechanisms played by TFAP2A-AS1 were unraveled comprehensively. Herein, a notable overexpressed TFAP2A-AS1 in NSCLC was observed by TCGA and our own cohort. An increased TFAP2A-AS1 level displayed a negative correlation with the overall survival of patients with NSCLC. Loss-of-function approaches illustrated that the absence of TFAP2A-AS1 weakened NSCLC cell proliferation, colony formation, migration and invasion in vitro. Also, interference of TFAP2A-AS1 caused in vivo tumor growth suppression. More >

Zhongyi Mu^*†1, Dan Dong^*1, Ning Wei^‡§, Mingli Sun^¶, Wei Wang^*, Yue Shao^*, Jian Gao^*, Ping Yin^*, Chenghai Zhao^*

Oncology Research, Vol.27, No.6, pp. 653-661, 2019, DOI:10.3727/096504018X15420748671075

Abstract The lncRNA AFAP1-AS1, oriented from an antisense direction to the protein-coding gene AFAP1 in the opposite strand, was upregulated in a variety of tumors and associated with poor prognosis, including lung cancer, breast cancer, ovarian cancer, and so on. However, the biological role of AFAP1-AS1 in clear cell renal cell carcinoma (ccRCC) is still unknown. We observed that AFAP1-AS1 expression was significantly upregulated in ccRCC tissues and that patients with high-level expression of AFAP1-AS1 had a shorter overall survival. Knockdown of AFAP1-AS1 markedly suppressed the progression of proliferation, invasion, migration, and EMT in ccRCC cells.… More >

Xuyang Wen^*, Xiaoping He^†, Feng Jiao^‡, Chunhui Wang^§, Yang Sun^‡, Xuequn Ren^¶, Qianwen Li^*

Oncology Research, Vol.25, No.4, pp. 629-640, 2017, DOI:10.3727/096504016X14768383625385

Abstract Gastric cancer (GC) is one of the main causes of cancer death. The tumor microenvironment has a profound effect on inducing tumor growth, metastasis, and immunosuppression. Fibroblast activation protein-a (FAP) is a protein that is usually expressed in fibroblasts, such as cancer-associated fibroblasts, which are major components of the tumor microenvironment. However, the role of FAP in GC progression and treatment is still unknown. In this study, we explored these problems based on GC patient samples and experimental models. We found that high FAP expression was an independent prognosticator of poor survival in GC patients. More >